You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 6,458,805


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 6,458,805
Title: Formulation of sulfonamides for treatment of endothelin-mediated disorders
Abstract:Formulations of pharmaceutically-acceptable salts of thienyl-, furyl- and pyrrolyl-sulfonamides and methods for modulating or altering the activity of the endothelin family of peptides using the formulations are provided. In particular, formulations of sodium salts of N-(isoxazolyl)-thienylsulfonamides, N-(isoxazolyl)furylsulfonamides and N-(isoxazolyl)-pyrrolylsulfonamides and methods using these sulfonamide salts for inhibiting the binding of an endothelin peptide to an endothelin receptor by contacting the receptor with the sulfonamide salt are provided. Methods for treating endothelin-mediated disorders by administering effective amounts of one or more of these sulfonamide salts or prodrugs thereof that inhibit or increase the activity of endothelin are also provided.
Inventor(s): Blok; Natalie (Houston, TX), Wu; Chengde (Houston, TX), Woodard; Patricia (Sugarland, TX), Keller; Karin (Houston, TX), Kogan; Timothy (Sugarland, TX)
Assignee: Texas Biotechnology Corporation (Houston, TX)
Application Number:09/792,237
Patent Claims:1. A pharmaceutically acceptable salt of a compound that has formula (I): ##STR14##

wherein: Ar.sup.1 is a group selected from five or six membered aromatic or heteroaromatic rings and bicyclic or tricyclic carbon or heterocyclic rings; Ar.sup.2 is selected from the group consisting of quinolyl, styryl, thienyl, furyl, isoquinolyl, pyrrolyl, benzofuranyl, pyridinyl, thionaphthyl and indolyl; and the salts are selected from the group consisting of pharmaceutically acceptable salts of alkali metals, salts of alkaline earth metals, salts of transition metals, polycationic counter ion salts, organic amine salts, salts of mineral acids and salts of organic acids.

2. The pharmaceutically acceptable salts of claim 1, wherein Ar.sup.2 is selected from the group consisting of thienyl, furyl and pyrrolyl groups.

3. The pharmaceutically acceptable salts of claim 1 that are alkali metal salts.

4. The pharmaceutically acceptable salts of claim 1 that are sodium salts.

5. The pharmaceutically acceptable salts of claim 1, wherein Ar.sup.1 is selected from the group consisting of isoxazolyl, pyridazinyl, thiazolyl, pyrimidinyl and phenyl groups.

6. The pharmaceutically acceptable salts of claim 1, wherein Ar.sup.2 has the formula IV: ##STR15##

in which X is S, O or NR.sup.11 in which R.sup.11 contains up to about 30 carbon atoms and is selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, alkylaryl, heterocyclyl, aralkyl, aralkoxy, cycloalkyl, cycloalkenyl, cycloalkynyl, C(O)R.sup.15 and S(O).sub.n R.sup.15 in which n is 0-2; R.sup.15 is hydrogen, alkyl, alkenyl, alkynyl, aryl, alkylaryl, heterocyclyl, aralkyl, aralkoxy, cycloalkyl, cycloalkenyl or cycloalkynyl; R.sup.11 and R.sup.15 are unsubstituted or are substituted with one or more substituents each selected independently from Z, which is hydrogen, halide, pseudohalide, alkyl, alkoxy, alkenyl, alkynyl, aryl, heterocyclyl, aralkyl, aralkoxy, cycloalkyl, cycloalkenyl, cycloalkynyl, OH, CN, C(O)R.sup.16, CO.sub.2 R.sup.16, SH, S(O).sub.n R.sup.16 in which n is 0-2, NHOH, NR.sup.12 R.sup.16, NO.sub.2, N.sub.3, OR.sup.16, R.sup.12 NCOR.sup.16 or CONR.sup.12 R.sup.16 ; R.sup.16 is hydrogen, alkyl, alkenyl, alkynyl, aryl, alkylaryl, heterocyclyl, aralkyl, aralkoxy, cycloalkyl, cycloalkenyl or cycloalkynyl; R.sup.12, which is selected independently from R.sup.11 and Z, is selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, alkylaryl, heterocyclyl, aralkyl, aralkoxy, cycloalkyl, cycloalkenyl, cycloalkynyl, C(O)R.sup.17 and S(O).sub.n R.sup.17 in which n is 0-2; and R.sup.17 is hydrogen, alkyl, alkenyl, alkynyl, aryl, alkylaryl, heterocyclyl, aralkyl, aralkoxy, cycloalkyl, cycloalkenyl or cycloalkynyl; each of R.sup.11, R.sup.12, R.sup.15 and R.sup.16 may be further substituted with the any of the groups set forth for Z; and R.sup.8, R.sup.9 and R.sup.10 are each independently selected as follows from (i) or (ii): (i) R.sup.8, R.sup.9 and R.sup.10, which each contain hydrogen or up to about 50 carbon atoms, are each independently selected from hydrogen, halide, pseudohalide, alkyl, alkoxy, alkenyl, alkynyl, aryl, aryloxy, heterocyclyl, aralkyl, aralkoxy, cycloalkyl, cycloalkenyl, cycloalkynyl, OH, CN, C(O)R.sup.18, acetoxy-(CH.dbd.CH)--, CO.sub.2 R.sup.18, SH, (CH.sub.2).sub.r C(O)(CH.sub.2).sub.n R.sup.18, (CH.sub.2).sub.r (CH.dbd.CH).sub.s (CH.sub.2).sub.n R.sup.18, (CH.sub.2).sub.r C(O)(CH.dbd.CH).sub.s (CH.sub.2).sub.n R.sup.18, (CH.sub.2).sub.r (CH.dbd.CH).sub.s C(O)(CH.sub.2).sub.n R.sup.18, (CH.sub.2).sub.r NH(CH.dbd.CH).sub.s (CH.sub.2).sub.n R.sup.18, (CH.sub.2).sub.r (CH.dbd.CH).sub.s NH(CH.sub.2).sub.n R.sup.18, (CH.sub.2).sub.r C(O)NH(CH.sub.2).sub.n R.sup.18, C(O)(CH.sub.2).sub.r NH(CH.sub.2).sub.n R.sup.18, (CH.sub.2).sub.r NH(CH.sub.2).sub.n R.sup.18, (CH.sub.2).sub.r R.sup.18, S(O).sub.m R.sup.18 in which m is 0-2, s, n and r are each independently 0 to 6, HNOH, NR.sup.18 R.sup.19, NO.sub.2, N.sub.3, OR.sup.18, R.sup.19 NCOR.sup.18 and CONR.sup.19 R.sub.18, in which R.sup.19 is selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, alkylaryl, alkoxy, aryloxy, heterocyclyl, aralkyl, aralkoxy, cycloalkyl, cycloalkenyl, cycloalkynyl, C(O)R.sup.20, and S(O).sub.n R.sup.20 in which n is 0-2; and R.sup.18 and R.sup.20 are independently selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, alkylaryl, heterocyclyl, alkoxy, aryloxy, aralkyl, aralkoxy, cycloalkyl, cycloalkenyl and cycloalkynyl; and any of the groups set forth for R.sup.8, R.sup.9 and R.sup.10 are unsubstituted or substituted with any substituents set forth for Z; or (ii) any two of R.sup.8, R.sup.9 and R.sup.10 with the carbon to which each is attached form an aryl, aromatic ring, heteroaromatic ring, carbocyclic or heterocyclic ring, which is saturated or unsaturated, containing from about 3 to about 1 6 members that is substituted with one or more substituents, each substituent is independently selected from Z; the other of R.sup.8, R.sup.9 and R.sup.10 is selected as in (i); and the heteroatoms are NR.sup.11, O, or S.

7. The pharmaceutically acceptable salts of claim 6, wherein Ar.sup.1 is an isoxazolyl, a thiazolyl, a pyrimidinyl, a pyridazinyl or a phenyl group.

8. The pharmaceutically acceptable salts of claim 6, wherein the compound has any of formulae V: ##STR16## R.sup.1 and R.sup.2 are either (i), (ii) or (iii) as follows: (i) R.sup.1 and R.sup.2 are each independently selected from H, NH.sub.2, NO.sub.2, halide, pseudohalide, alkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl, alkoxy, alkylamino, alkylthio, alkyloxy, haloalkyl, alkylsufinyl, alkylsulfonyl, aryloxy, arylamino, arylthio, arylsufinyl, arylsulfonyl, haloalkyl, haloaryl, alkoxycarbonyl, alkylcarbonyl, aminocarbonyl, arylcarbonyl, formyl, substituted or unsubstituted amido and substituted or unsubstituted ureido, in which the alkyl, alkenyl and alkynyl portions contain from 1 up to about 14 carbon atoms and are either straight or branched chains or cyclic, and the aryl portions contain from about 4 to about 16 carbons, except that R.sup.2 is not halide or pseudohalide; or, (ii) R.sup.1 and R.sup.2 together form --(CH.sub.2).sub.n, where n is 3 to 6; or, (iii) R.sup.1 and R.sup.2 together form 1,3-butadienyl.

9. The pharmaceutically acceptable salts of claim 6, wherein: if R.sup.8, R.sup.9 and R.sup.10 are each independently selected from (i), then each is selected with the proviso that if R.sup.8 is NR.sup.18 R.sup.19, OR.sup.18, R.sup.19 NCOR.sup.18, CONR.sup.19 R.sup.18, CO.sub.2 R.sup.18, (CH.sub.2).sub.r NH(CH.dbd.CH).sub.s (CH.sub.2).sub.n R.sup.18, (CH.sub.2).sub.r (CH.dbd.CH).sub.s NH(CH.sub.2).sub.n R.sup.18, (CH.sub.2).sub.r C(O)NH(CH.sub.2).sub.n R.sup.18, C(O)(CH.sub.2).sub.r NH(CH.sub.2).sub.n R.sup.18, (CH.sub.2).sub.r NH(CH.sub.2).sub.n R.sup.18 or (CH.sub.2).sub.r R.sup.18 and R.sup.18 is an aryl group containing 5 or 6 members, then the aryl group has at least two substituents; and if R.sup.8, R.sup.9 and R.sup.10 are each independently selected from (ii), then each is selected with the proviso that Ar.sup.2 is not 5-halo-3-loweralkylbenzo[b]thienyl, 5-halo-3-loweralkylbenzo[b]furyl or 5-halo-3-loweralkylbenzo[b]pyrrolyl.

10. The pharmaceutically acceptable salts of claim 8, wherein R.sup.8 is a phenylacetyl or phenylamino group.

11. The pharmaceutically acceptable salts of claim 10, wherein R.sup.9 and R.sup.10 are each hydrogen.

12. The pharmaceutically acceptable salts of claim 8, wherein: R.sup.1 is H, lower alkyl, halide or pseudohalide; and R.sup.2 is lower alkyl, lower alkenyl, lower alkynyl, lower haloalkyl or hydrogen.

13. The pharmaceutically acceptable salts of claim 12, wherein R.sup.1 is Br, Cl or lower alkyl; and R.sup.2 is lower alkyl, lower haloalkyl or hydrogen.

14. The pharmaceutically acceptable salts of claim 8, wherein: R.sup.8 is selected from among (CH.sub.2).sub.r C(O)(CH.sub.2).sub.n R.sup.18, (CH.sub.2).sub.r NH(CH.sub.2).sub.n R.sup.18, (CH.sub.2).sub.r NH(CH.sub.2).sub.n R.sup.18, (CH.sub.2).sub.r (CH.dbd.CH).sub.s (CH.sub.2).sub.n R.sup.18, (CH.sub.2).sub.r C(O)(CH.dbd.CH).sub.s (CH.sub.2).sub.n R.sup.18, (CH.sub.2).sub.r (CH.dbd.CH).sub.s C(O)(CH.sub.2).sub.n R.sup.18, (CH.sub.2).sub.r (CH.dbd.CH).sub.s NH(CH.sub.2).sub.n R.sup.18, C.dbd.N(OH)(CH.sub.2).sub.r R.sup.18, (CH.sub.2).sub.r C(O)NH(CH.sub.2).sub.n R.sup.18, C(O)(CH.sub.2).sub.r NH(CH.sub.2).sub.n R.sup.18, (CH.sub.2).sub.r NH(CH.dbd.CH).sub.s (CH.sub.2).sub.n R.sup.18, (CH.sub.2).sub.r C(O)NH(CH.sub.2).sub.n R.sup.18, (CH.sub.2).sub.r NH(CH.sub.2).sub.n R.sup.18, and (CH.sub.2).sub.r R.sup.18 ; and R.sup.9 and R.sup.10 are independently selected from hydrogen, halide, pseudohalide, alkyl, alkoxy, alkenyl, alkynyl, aryl, aryloxy, heterocyclyl, aralkyl, aralkoxy, cycloalkyl, cycloalkenyl, cycloalkynyl, OH, CN, C(O)R.sup.18, (OAC)CH.dbd.CHR.sup.18, CO.sub.2 R.sup.18, SH, (CH.sub.2).sub.r C(O)(CH.sub.2).sub.n R.sup.18, (CH.sub.2).sub.r (CH.dbd.CH).sub.s (CH.sub.2).sub.n R.sup.18, (CH.sub.2).sub.r C(O)(CH.dbd.CH).sub.s (CH.sub.2).sub.n R.sup.18, (CH.sub.2).sub.r (CH.dbd.CH).sub.s C(O)(CH.sub.2).sub.n R.sup.18, (CH.sub.2).sub.r NH(CH.dbd.CH).sub.s (CH.sub.2).sub.n R.sup.18, C.dbd.N(OH)(CH.sub.2).sub.r R.sup.18, (CH.sub.2).sub.r (CH.dbd.CH).sub.s NH(CH.sub.2).sub.n R.sup.18, (CH.sub.2).sub.r C(O)NH(CH.sub.2).sub.n R.sup.18, C(O)(CH.sub.2).sub.r NH(CH.sub.2).sub.n R.sup.18, (CH.sub.2).sub.r NH(CH.sub.2).sub.n R.sup.18, (CH.sub.2).sub.r R.sup.18, S(O).sub.m R.sup.18 in which m is 0-2, s, n and r are each independently 0 to 6, HNOH, NR.sup.18 R.sup.19, NO.sub.2, N.sub.3, OR.sup.18, R.sup.19 NCOR.sup.18 and CONR.sup.19 R.sup.18, in which R.sup.19 is selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, alkylaryl, alkoxy, aryloxy, heterocyclyl, aralkyl, aralkoxy, cycloalkyl, cycloalkenyl, cycloalkynyl, C(O)R.sup.20 and S(O).sub.n R.sup.20 in which n is 0-2; and R.sup.18 and R.sup.20 are independently selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, alkylaryl, heterocyclyl, alkoxy, aryloxy, aralkyl, aralkoxy, cycloalkyl, cycloalkenyl and cycloalkynyl.

15. The pharmaceutically acceptable salts of claim 14, wherein R.sup.8 is selected with the proviso that if R.sup.8 is (CH.sub.2).sub.r C(O)NH(CH.sub.2).sub.n R.sup.18, (CH.sub.2).sub.r C(O)NH(CH.sub.2).sub.n R.sup.18 or (CH.sub.2).sub.r R.sup.18, and R.sup.18 is phenyl, then the phenyl group is substituted at least two positions.

16. The pharmaceutically acceptable salts of claim 14, wherein R.sup.9 and R.sup.10 are each independently hydrogen, halide, loweralkyl, or halo loweralkyl.

17. The pharmaceutically acceptable salts of claim 16, wherein Ar.sup.2 is phenylaminocarbonylthienyl, phenylaminocarbonylfuryl, phenylaminocarbonylpyrrolyl, phenylacetylthienyl, phenylacetylfuryl, phenylacetylpyrrolyl, acetoxystyrylthienyl, acetoxystyrylfuryl or acetoxystyrylpyrrolyl.

18. The pharmaceutically acceptable salts of claim 17, wherein Ar.sup.2 is selected with the proviso that, when Ar.sup.2 is a phenylaminocarbonylthienyl, phenylaminocarbonylfuryl or phenylaminocarbonylpyrrolyl, then the phenyl group is substituted with at least two substituents selected from Z, which is hydrogen, halide, pseudohalide, alkyl, alkoxy, alkenyl, alkynyl, aryl, aryloxy, heterocyclyl, aralkyl, aralkoxy, cycloalkyl, cycloalkenyl, cycloalkynyl, OH, CN, C(O)R.sup.21, CO.sub.2 R.sup.21, SH, S(O).sub.n R.sup.21 in which n is 0-2, NHOH, NR.sup.22 R.sup.21, NO.sub.2, N.sub.3, OR.sup.21, R.sup.22 NCOR.sup.21 and CONR.sup.22 R.sup.21 ; R.sup.22 is selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, alkylaryl, heterocyclyl, aralkyl, alkoxy, aralkoxy, cycloalkyl, cycloalkenyl, cycloalkynyl, C(O)R.sup.23 and S(O).sub.n R.sup.23 in which n is 0-2; and R.sup.21 and R.sup.23 are independently selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, alkylaryl, heterocyclyl, aralkyl, aralkoxy, cycloalkyl, cycloalkenyl and cycloalkynyl.

19. The pharmaceutically acceptable salts of claim 14, wherein R.sup.11 is hydrogen, loweralkyl or aryl, which is unsubstituted or substituted with halogen, hydrogen or loweralkyl; R.sup.1 is hydrogen, halide, pseudohalide, loweralkyl or lower haloalkyl; and R.sup.2 is hydrogen, loweralkyl or lower haloalkyl.

20. The pharmaceutically acceptable salts of claim 8, wherein: Ar.sup.2 has formula VI: ##STR17## M is (CH.sub.2).sub.m C(O)(CH.sub.2).sub.r, (CH.sub.2).sub.m C(O)NH(CH.sub.2).sub.r, CH(OH)(CH.sub.2).sub.r, (CH.sub.2).sub.m (CH.dbd.CH)(CH.sub.2).sub.r, (CH.sub.2).sub.m C(O)(CH.sub.2).sub.s NH(CH.sub.2).sub.r, (CH.sub.2).sub.m (CH.dbd.CH)(CH.sub.2).sub.r, C.dbd.N(OH)(CH.sub.2).sub.r, (CH.sub.2).sub.m C(O)(CH.dbd.CH).sub.s NH(CH.sub.2).sub.r, CH(CH.sub.3)C(O)(CH.sub.2).sub.r, CH(CH.sub.3)C(O)(CH.sub.2).sub.m (CH.dbd.CH)(CH.sub.2).sub.r, (CH.sub.2).sub.r, (CH.sub.2).sub.r O or C(O)O, in which m, s and r are each independently 0 to 6; R.sup.31, R.sup.32, R.sup.33, R.sup.34 and R.sup.35 are each independently selected from (i) or (ii) as follows: (i) R.sup.31, R.sup.32, R.sup.33, R.sup.34 and R.sup.35 are each independently selected from among H, OH, NHR.sup.38, CONR.sup.38 R.sup.39, NO.sub.2, cyano, halide, pseudohalide, alkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl, alkoxy, alkylamino, alkylthio, haloalkyl, alkylsulfinyl, alkylsulfonyl, alkoxycarbonyl, alkylcarbonyl, alkenylthio, alkenylamino, alkenyloxy, alkenylsulfinyl, alkenylsulfonyl, alkoxycarbonyl, arylaminocarbonyl, alkylaminocarbonyl, aminocarbonyl, (alkyl-aminocarbonyl)alkyl, carboxyl, carboxyalkyl, carboxyalkenyl, alkylsulfonylaminoalkyl, cyanoalkyl, acetyl, acetoxyalkyl, hydroxyalkyl, alkyoxyalkoxy, hydroxyalkyl, (acetoxy)alkoxy, (hydroxy)alkoxy and formyl; or (ii) at least two of R.sup.31, R.sup.32, R.sup.33, R.sup.34 and R.sup.35, which substitute adjacent carbons on the ring, together form alkylenedioxy, alkylenethioxyoxy or alkylenedithioxy, which is unsubstituted or substituted by replacing one or more hydrogens with halide, loweralkyl, loweralkoxy or halo loweralkyl, and the others of R.sup.31, R.sup.32, R.sup.33, R.sup.34 and R.sup.35 are selected as in (i); and R.sup.38 and R.sup.39 are each independently selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, haloalkyl, alkylaryl, heterocyclyl, arylalkyl, arylalkoxy, alkoxy, aryloxy, cycloalkyl, cycloalkenyl and cycloalkynyl, with the proviso that when M is (CH.sub.2).sub.m C(O)NH(CH.sub.2).sub.r, then at least two of R.sup.31, R.sup.32, R.sup.33, R.sup.34 and R.sup.35 are not hydrogen.

21. The pharmaceutically acceptable salts of claim 20, wherein M is (CH.sub.2).sub.m C(O)(CH.sub.2).sub.r, (CH.sub.2).sub.m C(O)NH(CH.sub.2).sub.r, (CH.sub.2).sub.m (CH.dbd.CH)(CH.sub.2).sub.r, (CH.sub.2).sub.m C(O)(CH.sub.2).sub.s NH(CH.sub.2).sub.r, (CH.sub.2).sub.m (CH.dbd.CH)(CH.sub.2).sub.r, C.dbd.N(OH)(CH.sub.2).sub.r, CH(OH)(CH.sub.2).sub.r, (CH.sub.2).sub.r, (CH.sub.2).sub.r O or C(O)O.

22. The pharmaceutically acceptable salts of claim 20, wherein R.sup.31, R.sup.32, R.sup.33, R.sup.34 and R.sup.35 are selected from (i) or (ii): (i) R.sup.31, R.sup.32, R.sup.33, R.sup.34 and R.sup.35 are each independently selected from among loweralkyl, halide, haloloweralkyl, and loweralkoxy; and (ii) at least two of R.sup.31, R.sup.32, R.sup.33, R.sup.34 and R.sup.35 form ethylenedioxy or methylenedioxy and the others are selected as in (i).

23. The pharmaceutically acceptable salts of claim 20, wherein M is selected from the group consisting of ##STR18## R.sup.40 is hydrogen, alkyl, alkoxy, alkoxyalkyl, or haloalkyl.

24. The pharmaceutically acceptable salts of claim 20, wherein at least two of R.sup.31, R.sup.32, R.sup.33, R.sup.34 and R.sup.35, which substitute adjacent carbons on the ring, together form alkylenedioxy, alkylenethioxyoxy or alkylenedithioxy, which is unsubstituted or substituted by replacing one or more hydrogens with halide, loweralkyl, loweralkoxy or haloloweralkyl.

25. The pharmaceutically acceptable salts of claim 20, wherein at least one of R.sup.31 and R.sup.35 is other than hydrogen.

26. The pharmaceutically acceptable salts of claim 20, wherein Ar.sup.2 has formula VII: ##STR19##

in which W is CH.sub.2 or NH.

27. The pharmaceutically acceptable salts of claim 20, wherein M is selected from the group consisting of ##STR20##

28. The pharmaceutically acceptable salts of claim 23, wherein R.sup.40 is methyl, ethyl or hydrogen.

29. The pharmaceutically acceptable salts of claim 20, wherein R.sup.31, R.sup.32, R.sup.33, R.sup.34 and R.sup.35 are selected from (i) or (ii): (i) R.sup.31, R.sup.32, R.sup.33, R.sup.34 and R.sup.35 are each independently selected from loweralkyl, haloloweralkyl, phenyl, alkoxy, loweralkylsulfonylaminoloweralkyl, cyanoloweralkyl, acetyl, loweralkoxycarbonyl, cyano, OH, acetoxyloweralkyl, hydroxy loweralkyl, acetoxyloweralkoxy and loweralkoxycarbonyl; or (ii) R.sup.32 and R.sup.33 or R.sup.33 and R.sup.34 form alkylenedioxy, and the others of R.sup.31, R.sup.32, R.sup.33, R.sup.34 and R.sup.35 are selected as in (i).

30. The pharmaceutically acceptable salts of claim 20, wherein R.sup.31, R.sup.32, R.sup.33, R.sup.34 and R.sup.35 are selected from (i) or (ii): (i) R.sup.33 and R.sup.35 are other than hydrogen and are selected from loweralkyl and lower alkoxy, or (ii) at least one of R.sup.31 or R.sup.35 is other than hydrogen, and R.sup.32 and R.sup.33 or R.sup.33 and R.sup.34 form methylenedioxy or ethylenedioxy.

31. The pharmaceutically acceptable salts of claim 8, wherein R.sup.9 and R.sup.10 form a ring so that Ar.sup.2 is benzo[b]thienyl, benzo[b]furyl, or indolyl.

32. The pharmaceutically acceptable salts of claim 31, wherein R.sup.9 and R.sup.10 are selected with the proviso that there are one or more substituents and they are other than 5-halo and 3-loweralkyl, and the other of R.sup.8, R.sup.9 and R.sup.10 is selected from aryl, (CH.sub.2).sub.r R.sup.18, C(O)R.sup.18, CO.sub.2 R.sup.18, NR.sup.18 R.sup.19, SH, S(O).sub.n R.sup.18 in which n is 0-2, HNOH, NO.sub.2, N.sub.3, OR.sup.18, R.sup.19 NCOR.sup.18 and CONR.sup.19 R.sup.18.

33. The pharmaceutically acceptable salts of claim 1 that is a sodium salt and is a (phenylacetyl)thiophenesulfonamide.

34. The pharmaceutically acceptable salt of claim 33, wherein the (phenylacetyl)thiophenesulfonamide is N-(4-chloro-3-methyl-5-isoxazolyl)-2-[2-methyl-4,5-(methylenedioxy)phenyla cetyl]thiophene-3-sulfonamide.

35. The pharmaceutically acceptable salts of claim 1, wherein the pharmaceutically-acceptable salt is selected from the group consisting of calcium, lithium, magnesium, potassium, sodium hydrogen phosphate, disodium phosphate, sodium and zinc.

36. The pharmaceutically acceptable salts of claim 35, wherein the pharmaceutically-acceptable salt is a sodium hydrogen phosphate or is the sodium salt.

37. The pharmaceutically acceptable salt of claim 35, wherein the compound is N-(4-chloro-3-methyl-5-isoxazolyl)-2-[2-methyl-4,5-(methylenedioxy)phenyla cetyl]thiophene-3-sulfonamide.

38. The pharmaceutically acceptable salt of claim 36, wherein the compound is N-(4-chloro-3-methyl-5-isoxazolyl)-2-[2-methyl-4,5-(methylenedioxy)phenyla cetyl]thiophene-3-sulfonamide.

39. A pharmaceutical composition, comprising a pharmaceutically acceptable salt of claim 1 in a pharmaceutically acceptable vehicle.

40. A pharmaceutical composition, comprising a pharmaceutically acceptable salt of claim 33 in a pharmaceutically acceptable vehicle.

41. The composition of claim 39 that is formulated for oral administration.

42. The composition of claim 39 that is formulated for parenteral administration.

43. The composition of claim 39 that is formulated as a tablet or capsule.

44. A process for preparing a lyophilized powder, comprising: mixing a pharmaceutically acceptable salt of claim 1 with a sufficient amount of a solution containing a sugar to produce a solution thereof; sterile-filtering the resulting solution; and lyophilizing the filtered solution to produce a powder.

45. The process of claim 44, wherein the sugar is dextrose or sorbitol.

46. A lyophilized powder produced by the method of claim 44.

47. The powder of claim 46, wherein: the pharmaceutically-acceptable salt is a calcium, lithium, magnesium, potassium, sodium hydrogen phosphate, disodium phosphate, sodium or zinc salt.

48. The powder of claim 46, wherein the pharmaceutically-acceptable salt is a sodium salt.

49. The powder of claim 46, wherein the pharmaceutically acceptable salt is a salt of N-(4-chloro-3-methyl-5-isoxazolyl)-2-[2-methyl-4,5-(methylenedioxy)phenyla cetyl]thiophene-3-sulfonamide.

50. A combination, comprising the powder of claim 46 and a sterile vessel containing a single dosage or multiple dosage amount thereof.

51. The combination of claim 50, wherein the vessel is an ampoule, vial or syringe.

52. A pharmaceutical composition formulated for single dosage or multiple dosage administration prepared by mixing a single dosage of the powder of claim 46 with an aqueous medium.

53. The pharmaceutical composition of claim 52, wherein the final concentration of the sulfonamide salt is between about 1 mg/mL and about 500 mg/mL.

54. A combination comprising: a sterile vial containing the pharmaceutical formulation of claim 52.

55. The combination of claim 54, wherein the amount is for single dose administration.

56. The combination of claim 55, wherein the sterile vial also contains an amount of sterile water for injection wherein the final concentration of the sulfonamide sodium salt is 12.5 mg/mL or 25 mg/mL.

57. The composition of claim 43, comprising: about 50-100% by weight of the pharmaceutically-acceptable sulfonamide salts; about 0-25% by weight of a diluent or a binder; about 0-10% by weight of a disintegrant; and about 0-5% of a lubricant.

58. The composition of claim 57, wherein: the binder is microcrystalline cellulose; the diluent is lactose; the disintegrant is croscarmellose sodium or sodium starch glycolate; and the lubricant is magnesium stearate.

59. The composition of claim 57, wherein: the sulfonamide is N-(4-chloro-3-methyl-5-isoxazolyl)-2-[2-methyl-4,5-(methylenedioxy)phenyla cetyl]thiophene-3-sulfonamide.

60. A method for the treatment of endothelin-mediated diseases, comprising administering an effective amount of the composition of claim 39, wherein the effective amount is sufficient to ameliorate one or more of the symptoms of the disease.

61. The method of claim 60, wherein the pharmaceutically acceptable salt is a sodium salt of N-(4-chloro-3-methyl-5-isoxazolyl)-2-[2-methyl-4,5-(methylenedioxy)phenyla cetyl]thiophene-3-sulfonamide.

62. The method of claim 60, wherein the disease is selected from the group consisting of hypertension, cardiovascular disease, asthma, pulmonary hypertension, inflammatory diseases, ophthalmologic disease, menstrual disorders, obstetric conditions, wounds, gastroenteric disease, renal failure, immunosuppressant-mediated renal vasoconstriction, erythropoietin-mediated vasoconstriction endotoxin shock, pulmonary hypertension, anaphylactic shock and hemorrhagic shock.

63. An article of manufacture, comprising packaging material and a pharmaceutically acceptable salt of claim 1 within the packaging material, wherein the pharmaceutically acceptable salt is effective for antagonizing the effects of endothelin, ameliorating the symptoms of an endothelin-mediated disorder, or inhibiting the binding of an endothelin peptide to an ET receptor with an IC.sub.50 of less than about 10 .mu.M, and the packaging material includes a label that indicates that the pharmaceutically acceptable salt is used for antagonizing the effects of endothelin, inhibiting the binding of endothelin to an endothelin receptor or treating an endothelin-mediated disorder.

64. The article of manufacture of claim 63, wherein the pharmaceutically acceptable salt is a sodium salt.

65. The article of manufacture of claim 64, wherein the pharmaceutically acceptable salt is a salt of N-(4-chloro-3-methyl-5-isoxazolyl)-2-[2-methyl-4,5-(methylenedioxy)phenyla cetyl]thiophene-3-sulfonamide.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.